With their ability to deliver precisely targeted therapies for a growing number of cancer types, it\u2019s no wonder that the development and approval of ADCs is expanding, with 21 now approved worldwide and more than 350 in clinical development. Because the antibody is generally less stable than the small-molecule cytotoxic agent, 90% of commercially available ADCs are manufactured as lyophilized powders that are reconstituted at the point of care, a process that must be optimized to address the variation in ADC antibody and payload.<\/p>\n
In this whitepaper, learn more from the Simtra BioPharma Solutions team about the essential role of lyophilization in the development and manufacture of ADCs, and how Simtra ensures that the lyophilization process is optimized to ensure safety and efficacy.<\/p>\n","protected":false},"featured_media":0,"template":"","meta":{"_acf_changed":false,"_relevanssi_hide_post":"","_relevanssi_hide_content":"","_relevanssi_pin_for_all":"","_relevanssi_pin_keywords":"","_relevanssi_unpin_keywords":"","_relevanssi_related_keywords":"","_relevanssi_related_include_ids":"","_relevanssi_related_exclude_ids":"","_relevanssi_related_no_append":"","_relevanssi_related_not_related":"","_relevanssi_related_posts":"","_relevanssi_noindex_reason":""},"class_list":["post-2232","resource","type-resource","status-publish","hentry"],"acf":[],"yoast_head":"\n